NASDAQ:HUMA Humacyte (HUMA) Stock Price, News & Analysis $0.59 +0.01 (+1.83%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$0.59 +0.00 (+0.07%) As of 09/18/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Humacyte Stock (NASDAQ:HUMA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Humacyte alerts:Sign Up Key Stats Today's Range$0.57▼$0.6150-Day Range$0.55▼$0.7452-Week Range$0.53▼$2.55Volume6.99 million shsAverage Volume4.92 million shsMarket Capitalization$162.68 millionP/E RatioN/ADividend YieldN/APrice Target$6.54Consensus RatingModerate Buy Company Overview Humacyte, Inc. is a biotechnology company developing and commercializing off-the-shelf, bioengineered human tissues for use in vascular repair and regenerative medicine. Its technology is based on human acellular tissue-engineered vessels, which are designed to provide durable vascular conduits without requiring a patient-specific donor vessel. The company’s lead product, Symvess, is an acellular tissue-engineered vessel approved by the U.S. Food and Drug Administration for the treatment of extremity arterial injuries in adults when emergency vascular repair is needed and a suitable vein is unavailable or inappropriate. Humacyte is also advancing its vascular products for potential use in other areas, including vascular trauma, arteriovenous access for hemodialysis, and selected cardiovascular and pediatric applications. Founded in 2004 and headquartered in Durham, North Carolina, Humacyte was co-founded by Dr. Laura Niklason, who serves as chief executive officer. The company’s development and commercial activities are primarily focused on the United States, with its technology intended for use by hospitals and medical professionals in vascular and surgical care.AI Generated. May Contain Errors. Read More Humacyte Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks64th Percentile Overall ScoreHUMA MarketRank™: Humacyte scored higher than 64% of companies evaluated by MarketBeat, and ranked 286th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingHumacyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialHumacyte has a consensus price target of $6.54, representing about 1,017.1% upside from its current price of $0.59.Amount of Analyst CoverageHumacyte has only been the subject of 3 research reports in the past 90 days.Read more about Humacyte's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Humacyte are expected to grow in the coming year, from ($0.40) to ($0.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Humacyte is -1.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Humacyte is -1.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHumacyte has a P/B Ratio of 29.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Humacyte's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted11.08% of the float of Humacyte has been sold short.Short Interest Ratio / Days to CoverHumacyte has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Humacyte has recently decreased by 6.66%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHumacyte does not currently pay a dividend.Dividend GrowthHumacyte does not have a long track record of dividend growth. News and Social Media2.3 / 5News SentimentN/A News SentimentHumacyte has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Healthcare companies.Search InterestOnly 10 people have searched for HUMA on MarketBeat in the last 30 days. This is a decrease of -23% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Humacyte to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Humacyte insiders have not sold or bought any company stock.Percentage Held by Insiders3.10% of the stock of Humacyte is held by insiders.Percentage Held by Institutions44.71% of the stock of Humacyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Humacyte's insider trading history. Receive HUMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Humacyte and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HUMA Stock News HeadlinesHumacyte to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 10, 2026 | globenewswire.comHumacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 MonthsSeptember 9, 2026 | globenewswire.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.September 19 at 1:00 AM | Base Camp Trading (Ad)Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMASeptember 4, 2026 | businesswire.comHumacyte, Inc. (HUMA) Stock Earnings Call Transcripts - Yahoo FinanceSeptember 2, 2026 | finance.yahoo.comHumacyte, Inc. (HUMA) Stock Price, News, Quote & History - Yahoo FinanceAugust 27, 2026 | finance.yahoo.comHumacyte Plans FDA Filing for Acellular Tissue Engineered Vessel in Dialysis AccessAugust 24, 2026 | finance.yahoo.comHumacyte Plans November 2026 Supplemental BLA Submission for ATEV Dialysis Access Based on Phase 3 DataAugust 24, 2026 | quiverquant.comQSee More Headlines HUMA Stock Analysis - Frequently Asked Questions How have HUMA shares performed this year? Humacyte's stock was trading at $0.9605 at the beginning of 2026. Since then, HUMA stock has decreased by 39.0% and is now trading at $0.5856. How were Humacyte's earnings last quarter? Humacyte, Inc. (NASDAQ:HUMA) released its quarterly earnings data on Wednesday, August, 12th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.11) by $0.05. The firm earned $0.41 million during the quarter, compared to analyst estimates of $1.04 million. Humacyte had a negative trailing twelve-month return on equity of 983.32% and a negative net margin of 4,556.29%. Read the conference call transcript. Who are Humacyte's major shareholders? Top institutional investors of Humacyte include Alyeska Investment Group L.P. (2.23%), BlackRock Inc. (2.18%), GSA Capital Partners LLP (0.45%) and HBK Investments L P (0.28%). Insiders that own company stock include Shamik J Parikh, Dale A Sander, Gordon M Binder, Kathleen Sebelius, Michael T Constantino, William John Scheessele, Heather Ledbetter Prichard, Laura E Niklason and Brady W Dougan. View institutional ownership trends. How do I buy shares of Humacyte? Shares of HUMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Humacyte own? Based on aggregate information from My MarketBeat watchlists, some other companies that Humacyte investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Intel (INTC), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG). Company Calendar Last Earnings8/12/2026Today9/19/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 HUMA's financial health is in the Yellow zone, according to TradeSmith. HUMA has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:HUMA CIK1818382 Webwww.humacyte.com Phone919-313-9633FaxN/AEmployees184Year Founded2004Price Target and Rating Average Price Target for Humacyte$6.54 High Price Target$25.00 Low Price Target$1.00 Potential Upside/Downside+1,017.1%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$40.83 million Net Margins-4,556.29% Pretax Margin-4,560.82% Return on Equity-983.32% Return on Assets-88.84% Debt Debt-to-Equity Ratio2.07 Current Ratio6.21 Quick Ratio5.74 Sales & Book Value Annual Sales$2.04 million Price / Sales79.74 Cash FlowN/A Price / Cash FlowN/A Book Value$0.02 per share Price / Book29.28Miscellaneous Outstanding Shares277,800,000Free Float269,186,000Market Cap$162.68 million OptionableOptionable Beta2.45 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:HUMA) was last updated on 9/19/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Humacyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Humacyte With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
